Trigen Completes €26.5 Million Financing Round

Munich, Germany, and London, UK, 11 October 2005. Trigen Holdings AG, the cardiovascular drug discovery and development company, today announced the completion of a €26.5m (US$31.9m) financing round with an international syndicate of new and existing investors. Wellington Partners (Munich, Germany), with insiders HealthCap (Stockholm, Sweden) and 3i (London, UK), co-led the round which included SR One (the venture investment subsidiary of GSK, Pennsylvannia, USA), Quintiles PharmaBio Development (North Carolina, USA), Quest for Growth (Leuven, Belgium), BIT (London, UK) and Merifin (Brussels, Belgium) along with other private investors.